share for Mexican pharmaceutical firms in the private sector.
Current Industry Position-
The Mexican pharmaceutical industry has over 400 companies that produce pharmaceutical products in the country. The market is largely dominated by multinational companies – to the extent of 80 percent of total pharma production in the country. There is no single company that occupies more than 10 percent in the private sector. 36 companies cover almost 80 percent of the market. Leading local producers include Armstrong Laboratorios, Laboratorios Liomont and SicorDomestic companies are small and fragmented. More than 50% of the pharmaceutical companies are located in Mexico City (Distrito Federal), followed by around 10% in Estado de México; 12% in Jalisco; 6% in Puebla and 4% in Morelos.
Traditionally, Mexican firms have focused on the manufacture of generic products, for which patents have expired, targeting the public sector as their main customer. Innovative pharmaceuticals are almost entirely limited to multinational firms that transfer advanced technologies from their parent companies.
Parallel markets of drugs in Mexico:
1. Branded patented products.
2. Branded generics.
3. Interchangeable Generics (GIs).
4. Similares- generics that have not obtained bio-equivalence certification
5. Public health sector generics.
Generic market- Mexico offers a significant untapped growth potential for generic drugs. The total market for generics is projected at US$2.2 billion or 11 times larger than the current market estimates of US$200 million.